Cite
HARVARD Citation
Sun, G. et al. (n.d.). 440 Activity and safety of camrelizumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced non-small-cell lung cancer. Journal for immunotherapy of cancer. pp. A267-A268. [Online].